Child and adolescent chronic fatigue syndrome/myalgic encephalomyelitis: where are we now?
Gregorowski, Anna, Simpson, Jane, Segal, Terry Y · Current opinion in pediatrics · 2019 · DOI
Quick Summary
This review looked at what we currently know about ME/CFS in children and teenagers, including what might cause it, how it affects their lives, and what treatments might help. The researchers found that ME/CFS is a serious condition that varies greatly from person to person, and that we still don't fully understand what causes it or have proven treatments that work for everyone. They highlight that more research is urgently needed, especially to help the most severely affected young people.
Why It Matters
This review is important because ME/CFS in young people is severely understudied despite causing substantial disability and family impact. Understanding the current evidence gaps helps guide research priorities and informs clinical guideline development, ultimately improving care and outcomes for affected children and adolescents who currently lack proven, evidence-based treatments.
Observed Findings
ME/CFS in children and adolescents presents heterogeneously with variable severity and clinical features
Comorbidities including mood disorders and pain are frequently observed in affected young people
Online cognitive behavioral therapy and the Lightning Process (when added to medical care) show promise as potential treatments
Current evidence is fragmented due to differing diagnostic criteria across studies
The severely affected subgroup of children remains poorly studied and has limited treatment evidence
Inferred Conclusions
ME/CFS in children and adolescents requires further large-scale, well-designed research using standardized diagnostic criteria
Current treatment evidence is insufficient to recommend one approach universally, though some interventions show preliminary promise
The heterogeneous nature of pediatric ME/CFS suggests multiple underlying mechanisms or disease subtypes may exist
More research is critical to identify effective treatments particularly for severely affected young people
Remaining Questions
What are the primary biological causes or mechanisms underlying ME/CFS in children and adolescents?
What This Study Does Not Prove
This review does not establish definitive causes of pediatric ME/CFS or prove the superiority of any single treatment approach. The heterogeneity of studies examined and small sample sizes limit the ability to draw firm conclusions about treatment efficacy, and correlation between potential triggers and disease onset does not establish causation.
Which treatment approaches are most effective for different subgroups of affected youth, particularly the severely ill?
How do long-term outcomes in pediatric ME/CFS compare across different treatment modalities and patient characteristics?
What role do viral infections, immune dysfunction, and other proposed precipitating factors play in disease development and maintenance in young people?